A major focus in the current discovery of drugs targeting nuclear receptors (NRs) is identifying drugs with reduced side effects by improving selectivity, not only from other receptors but also by selective modulation of the NR of interest. Cellular assays not only provide valuable information on functional activity, potency, and selectivity but also are ideally suited for differentiating partial agonists and antagonists. The ability to partially activate a receptor is believed to be closely tied to the ability to selectively modulate the NR, resulting in expression of a subset of the normally regulated genes. To this end, the authors have built a complete panel of cell-based steroid hormone receptor assays for the androgen receptor, estrogen receptor alpha, estrogen receptor beta, glucocorticoid receptor, mineralocorticoid receptor, and progesterone receptor by stably engineering a Gal4 DNA-binding domain/nuclear receptor ligand-binding domain fusion protein into an upstream activation sequence beta-lactamase reporter cell line. Each assay was validated with known agonists and antagonists for correct pharmacology and high-throughput compatibility. To demonstrate the utility of these assays, the authors profiled 35 pharmacologically relevant compounds in a dose-response format against the panel in both agonist and antagonist modes. The results demonstrated that selective estrogen receptor modulators can be identified and differentiated, as well as mixed and partial agonists and antagonists easily detected in the appropriate assays. Importantly, a comparison of the chimeric assays with fulllength reporter gene assay data from the literature shows a good degree of correlation in terms of selectivity and pharmacology of important ligands. Taken together, these steroid hormone receptor assays provide good selectivity, sensitivity, and appropriate pharmacology for high-throughput screening and selectivity profiling of modulators of steroid hormone receptors. (Journal of Biomolecular Screening 2008:755-765) 
INTRODUCTION
N UCLEAR RECEPTORS (NRS) ARE A SUPERFAMILY OF TRAN-SCRIPTION FACTORS that mediate the effects of hormones and other ligands by modulating the expression of specific genes involved in many cellular functions such as development, reproduction, and metabolism. One of the subclasses in the NR superfamily is the steroid family of nuclear receptors, which includes the androgen receptor (AR), progesterone receptor (PR), mineralocorticoid receptor (MR), glucocorticoid receptor (GR), and the estrogen receptors alpha and beta (ER alpha and ER beta). Steroid NRs bind various steroid ligands, which leads to homodimerization of the receptor and binding to specific promoter elements to drive the expression of downstream genes that control reproduction and development (AR, PR, ER alpha, and ER beta), metabolic functions (MR), CNS functions (ER alpha and beta), and lipid metabolism and energy homeostasis (GR). 1, 2 Alterations in the functions of these receptors can lead to endocrine-related diseases, such as cancer, cardiovascular disease, and inflammation. Some of the most successful drugs currently on the market for contraception, hypertension, prostate cancer, breast cancer, and inflammation are modulators of steroid hormone receptors. 2 For instance, PR ligands have many therapeutic uses in a variety of women's health concerns, including contraception, postmenopausal hormone replacement therapy, and treatment of reproductive disorders. 3 Selective estrogen receptor modulators (SERMs) are also important clinically and commonly used in contraception, the prevention and treatment of postmenopausal symptoms, treatment of hormone-dependent breast cancer, and osteoporosis. 4 Because of the large number of regulating cofactors, interacting proteins and ligands, varied tissue distribution, and variation in response elements, elucidation of NR biology is very challenging. Many drugs currently targeting nuclear receptors have significant off-target side effects. Glucocorticoids are the most commonly used anti-inflammatory and immunosuppressive drugs but are often accompanied by severe and sometimes irreversible side effects, such as weight gain, diabetes, hypertension, sleep disorders, behavioral changes, glaucoma, osteoporosis, and others. Many of these side effects are so severe with sustained use that it prevents the full anti-inflammatory potential of these drugs from being attained. 5, 6 Sometimes the off-target side effects are due to a lack of specificity of the compound for a particular steroid receptor, as it is common to have a particular compound interact with more than 1 steroid hormone receptor. For example, progestins are commonly used for women's health issues, and although they have many therapeutic uses in oral contraceptives and hormone therapy, they often have unwanted side effects because of their interaction with other steroid receptors. 3 Many androgens also suffer a loss in their therapeutic window for frailty, sexual dysfunction, and osteoporosis due to their associated side effects, and often times, these drugs are not widely used because of these side effects. 7 Some compounds can have mixed effects against the same receptor in different tissues because of varying levels of coregulator expression in those tissues. Examples of commonly used drugs that have mixed effects on the same receptor in different tissues are the SERMs such as raloxifene and tamoxifen. Raloxifene acts as an antagonist in breast tissue and an agonist in bone, whereas tamoxifen has the additional effect of being an agonist in the uterus. 8 Because of these properties, both drugs decrease breast cancer growth and prevent bone loss, but tamoxifen causes an increased chance for the development of cancer of the uterus. Selective nuclear receptor modulators (SNuRMs) in general are of increasing interest in drug discovery because of their ability to exert a modified effect on the receptor compared with a full agonist or antagonist, resulting in expression of a subset of the normally regulated set of genes. The strategy is to find SNuRMs that only activate the genes associated with the pathology and not those that are likely associated with unwanted side effects.
Current assays commonly used to address potency and selectivity of nuclear receptor modulators include a variety of biochemical and cellular assays. There are many formats of biochemical ligandbinding assays, such as radiometric assays or fluorescence polarization assays. The limitation of these types of assays is the inability to detect the functional response a ligand or modulator would have on its receptor. Commonly used cell-based assays are reporter gene assays, using endogenous or exogenous full-length receptors. The major drawback of the full-length or endogenous cellular assays is the limitation of selectivity because different nuclear receptors can bind to the same or similar response elements and ligands. 9 To address these issues, we have built a panel of steroid hormone receptor cellular assays by stably engineering expression of Gal4 DNA-binding domain (DBD)/NR ligand-binding domain (LBD) chimeras in a parental HEK293 cell line containing the betalactamase reporter gene under transcriptional control of an upstream activation sequence (UAS-bla). Single cell clones for each NR target were isolated by fluorescence-activated cell sorting (FACS) based on their response to their appropriate primary stimulus. The best responding clone was optimized for various assay parameters, validated using several known agonists and antagonists for each target, and tested for proper rank order potency. To demonstrate the utility of these engineered cell lines in a reporter assay, we screened 35 compounds in a dose-response format against all 6 steroid NR cell lines, in both agonist and antagonist modes. The results establish that these assays display appropriate pharmacology, rank order potency, and selectivity profile of the ligands tested and are robust enough for high-throughput screening (HTS).
MATERIALS AND METHODS

Reagents
Hydroxyflutamide was obtained from LKT labs (St. Paul, MN). 4′-hydroxy-tamoxifen, 5 α Androstan-17β-ol-3-one (DHT, dihydrotestosterone), anthralin (Dithranol), cyproterone acetate, 17β-estradiol (E2), fluticasone propionate, genistein, miconazole, prednisone, progesterone, raloxifene, spironolactone, and testosterone were from Sigma (St. Louis, MO). Aldosterone, cortisol, cortisone, danazol, diethylstilbestrol (DES), dexamethasone, dehydroepiandrosterone (DHEA), estrone, ethisterone, fludrocortisone, methylprednisolone, mifepristone/RU486, and norethindrone were from Steraloids (Newport, RI). Corticosterone was from EMD BioSciences (San Diego, CA). Daunorubicin HCL, diarylpropionitrile (DPN), ICI 182.780, and propyl pyrazole triol (PPT) were from Tocris Bioscience (Ellisville, MO). Mometasone furoate was from U.S. Pharmacopeia (Rockville, MD). Methyltrienelone (R1881) and promegestone (R5020) were from PerkinElmer (Waltham, MA). Cell culture media and supplements, Lipofectamine 2000, ViraPower™ lentiviral expression kit, and LiveBLAzer substrate loading solution were from Invitrogen (Carlsbad, CA). Matrigel™ matrix was from BD Biosciences (Bedford, MA). Tissue culture and assay plates were from Corning (Corning, NY).
Vectors used
For AR, ER alpha, ER beta, and PR, plasmids were created containing a fusion of the N-terminal of the Gal4 DBD and part of the hinge and the entire LBD of each respective NR target. The accession number and amino acids represented for each target are as follows:
Generation of target-specific NR-LBD cell lines
The UAS-bla HEK293T or UAS-bla GripTite™ master reporter cell lines (Invitrogen) were transduced with lentivirus created from the NR target-specific plasmids according to manufacturer's instructions and selected for zeocin resistance. The zeocin-resistant pools were starved in assay media (phenol red-free Dulbecco's modified Eagle's medium [DMEM], 2% charcoal/dextran-stripped fetal bovine serum [FBS], 0.1 mM nonessential amino acids [NEAA], 1 mM sodium pyruvate, 100 U/mL penicillin, and 100 μg/mL streptomycin) overnight and then stimulated with the appropriate primary ligand overnight (AR: R1881, ER alpha and ER beta: 17β-estradiol, and PR: R5020). Responding cells were collected into single-cell clones onto 96-well plates using FACS. The clones that displayed the highest fold signal change with their respective ligand compared with a DMSO control were selected and expanded, and the best responding clone for each NR was chosen for assay development. The GR and MR cell lines were created using a different approach as previously described. 10
Beta-lactamase reporter assays
The MR, GR, and PR cell lines were cultured in DMEM containing 10% dialyzed FBS, 0.1 mM NEAA, 1 mM sodium pyruvate, 25 mM HEPES, 100 U/mL penicillin, and 100 μg/mL streptomycin on Matrigel™-coated flasks. ER alpha and ER beta cell lines were cultured in DMEM containing 10% dialyzed FBS, 0.1 mM NEAA, 1 mM sodium pyruvate, 100 U/mL penicillin, and 100 μg/mL streptomycin. The AR cell line was cultured in DMEM containing 10% dialyzed FBS, 0.1 mM NEAA, 25 mM HEPES, 100 U/mL penicillin, and 100 μg/mL streptomycin. Assays were performed in a standardized assay medium containing phenol redfree DMEM, 2% charcoal/dextran-stripped FBS, 0.1 mM NEAA, 1 mM sodium pyruvate, 100 U/mL penicillin, and 100 μg/mL streptomycin. Assays were performed as indicated below in agonist or antagonist assay sections. After subtracting the average fluorescence intensity from the cell-free control wells, the 460 nm/530 nm emission ratio was calculated. Response ratio is a measurement of the assay window and is calculated as the 460 nm/530 nm emission ratio of the stimulated wells divided by the 460 nm/530 nm emission ratio of the unstimulated wells. Response ratios were plotted against test ligand concentration in log scale and then analyzed using Prism software (GraphPad Software, Inc., San Diego, CA). Sigmoidal dose-response equation with varying slope was used to fit the data and generate EC 50 and IC 50 values. Z′ factor values were calculated as Z′ factor = 1 -[(3 × SD unstim + 3 × SD maxstim )/ (avg maxstim -avg unstim )].
Compound profiling
Compounds were initially diluted to 10 mM stocks in either DMSO (Fisher, Hampton, NH) or ethanol (Sigma). The 384-well master dilution plates were then made by serially diluting across the plate, starting at 10 mM and decreasing in half-logs to 0.318 nM in 100% DMSO. The 96-well source plates were made using the Multimek™ 96 (Beckman Coulter, Fullerton, CA) by diluting the serial dilutions from the 384-well master plates 1:100 in assay medium. The Multimek™ 96 was used to stamp 4 μL (10× of final concentration) from the 96-well source plate into 384-well black-wall, clear-bottom assay plates.
Agonist assays
The 10× test compounds were obtained in prestamped, 384well black-wall, clear-bottom assay plates. Cells were harvested and added to the test compounds at 20,000 cells/well in 32 μL of assay medium. Plates were incubated for 16 h at 37°C /5% CO 2 . LiveBLAzer substrate was added and plates were incubated for 90 to 120 min at room temperature. Plates were read on a CytoFluor ® 4000 Fluorescence Plate Reader from PerSeptive Biosystems (Foster City, CA).
Antagonist assays
The 10× test compounds were obtained in prestamped, 384well black-wall, clear-bottom assay plates. Cells were harvested and added to the test compounds at 20,000 cells/well in 32 μL of assay medium. Plates were incubated for 30 to 60 min at 37°C /5% CO 2 . Primary stimulus (at a predetermined EC 80 ) was added to all test compound wells. Plates were incubated for 16 h at 37 °C/5% CO 2 . LiveBLAzer substrate was added and plates were incubated for 90 to 120 min at room temperature. Plates were read on a CytoFluor ® 4000 Fluorescence Plate Reader from PerSeptive Biosystems. Primary stimuli used were as follows: AR = 1.23 nM DHT; ER alpha and ER beta = 0.2 and 0.8 nM 17βestradiol, respectively; GR = 1.5 nM dexamethasone; MR = 1.2 nM aldosterone; and PR = 25 nM progesterone.
RESULTS
Creation and validation of the steroid receptor cell lines
To develop the steroid receptor assays, we first created lentivirus vectors consisting of the Gal4 DBD fused to the LBD of the respective steroid hormone receptors. Lentivirus was then made and transduced into a UAS-bla master cell line and selected for stable integrants using selection antibiotics. Single clones of each steroid receptor that responded to primary ligand were isolated by FACS. The best responding clone for each steroid receptor was expanded and further validated in response to its primary ligand ( Fig. 1) . AR responded to R1881 with an EC 50 value of 0.44 nM, consistent with the literature reference value. 11 17βestradiol is a widely used ER alpha and beta ligand, 12 and it stimulated the reporter activation in our Gal4 ER alpha/beta LBD assays with EC 50 values of 0.07 nM and 0.5 nM, respectively. Dexamethasone, aldosterone, and R5020 are ligands for GR, MR,
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and PR, respectively, and stimulated the beta-lactamase reporter activation in our GR-LBD, MR-LBD, and PR-LBD cells with EC 50 values of 1.7 nM, 0.4 nM, and 0.3 nM, respectively, consistent with literature values. [13] [14] [15] All 6 assays demonstrated good assay windows and good Z′ values ( Table 1) , indicating that these assays are suitable for high-throughput profiling.
Compound profiling
To demonstrate the utility of these cell lines for selectivity profiling, we assayed 35 known compounds with the full panel of steroid receptor assays in both agonist and antagonist modes. The compounds were tested in a dose-response format, and EC 50 and IC 50 results are summarized in Table 2 . A color-coded heat map was generated to reflect the potencies of the compounds in these assays. Subnanomolar compounds (<1 nM) were the most potent and are colored in red. Low nanomolar range compounds (1-100 nM) are colored in dark orange, and high nanomolar/ submicromolar compounds (100-1000 nM) are colored in light orange. Compounds in the low micromolar range (1000-10,000 nM) are the least potent and are colored in yellow. Compounds that showed either no effect or a very weak effect are left in white and have their potencies listed as >10,000 nM. In addition, compounds that displayed partial agonist or antagonist activities are listed as such within the table itself. The control ligands demonstrated similar EC 50 /IC 50 values in this profiling experiment to those obtained during assay validation.
Selectivity profile of SERMs
The ability to determine the potency and selectivity of SERMs is a key function of any ER screening tool, as there are many pharmacologically relevant compounds that have opposing effects in the 2 different ER isoforms. Subtype-selective ligands for the ERs are highly desirable for a variety of therapeutic areas, such as breast cancer treatment, hormone replacement therapy, and osteoporosis. Several known SERMs were included in our profiling experiment. As expected, DPN displayed selectivity for ER beta over ER alpha, with EC 50 values of 1.4 and 21 nM, respectively ( Fig. 2A) , consistent with literature values for in vitro binding affinity of DPN (0.85 and 66 nM for ER beta and ER alpha, respectively). 16 PPT is known to activate the alpha isoform but not the beta isoform of the estrogen receptor. 16 As expected, PPT was only active in our ER alpha assay, with an EC 50 value of 2.5 nM, and showed no activity toward ER beta (Fig. 2B) . DPN and PPT showed no activity toward AR, GR, MR, or PR. Raloxifene displays mixed antagonist/agonist properties for ER alpha but is a pure antagonist for ER beta. 12 In our assays, raloxifene was a partial but potent agonist for ER alpha, with an EC 50 of 0.05 nM, and showed no agonist activity with ER beta. It is a full antagonist for both ER assays, with IC 50 values of 0.95 and 4.9 nM for ER alpha and beta, respectively (Fig. 3) . Raloxifene also acts as an inverse agonist toward ER beta, suppressing the background reporter gene expression. This mixed activity and isoform selectivity is consistent with literature using full-length ER alpha and ER beta reporter cell lines. 12 Raloxifene had very little effect on the other steroid receptors in our assays. Taken together, using our panel of steroid receptor assays, one can effectively distinguish SERMs from other nonselective compounds and generate specificity profiles of SERMs.
Partial and full agonists and antagonists
These cell-based assays are also capable of distinguishing partial from full agonistic or antagonistic properties, which is not always easily discernable using biochemical assays. The SERM raloxifene, described above, is one example of how these full and partial activities can be easily detected in these assays. 4hydroxy-tamoxifen is another estrogen receptor ligand with both partial and full activities against the different estrogen receptor isoforms. It is known that this compound is a partial ER alphaselective agonist but an antagonist for both alpha and beta isoforms. 12 In our assays, 4-hydroxy-tamoxifen revealed its activity as a very potent but partial ER alpha agonist, with an EC 50 value of 0.03 nM, while having no agonist activity against the beta isoform of ER. This compound is a full antagonist for both isoforms, with IC 50 values of 0.95 nM and 0.19 nM for ER alpha and ER beta, respectively ( Table 2) . Another example of a compound with mixed full or partial activities is cyproterone acetate (CPA). Originally derived from a 17α-hydroxyprogesterone, CPA is known to possess progestogenic activity, but it is primarily employed clinically as an antiandrogen. 17 In an HTS campaign several years ago, it was discovered that CPA also possessed antiglucocorticoid activity. 17 CPA is commonly used to treat inoperable prostate cancer in men and is used to treat acne or virilizing syndromes in women. The compound profile of CPA in our assays revealed its activity as a partial antagonist for AR (IC 50 = 37 nM), a full antagonist for GR (IC 50 = 16 nM), and a partial but very potent agonist for PR (EC 50 = 0.21 nM; Fig. 4) , consistent with the literature for the various steroid receptors. 11, 17 CPA displayed little or no activity against the other NRs.
Comparison with literature values using full-length receptors
When a chimeric fusion protein or LBD-based assay is used, a concern is that the pharmacology of compounds in the LBD assay might be significantly different from the results of an assay using a full-length receptor. To address this concern, we took a close Mixed agonist/antagonist properties of raloxifene. Cells were serum starved the day prior to assay and plated in a 384-well assay plate. For agonist mode, cells were stimulated with raloxifene for 16 h prior to the beta-lactamase assay (as described in Materials and Methods) (ER alpha, ; ER beta, ). For antagonist mode, cells were stimulated with raloxifene for 30 to 60 min prior to stimulation with EC 80 amounts of 17β-estradiol (0.2 nM and 0.8 nM for ER alpha and ER beta, respectively) for 16 h prior to the beta-lactamase assay (as described in Materials and Methods) (ER alpha, ; ER beta, ). Raloxifene is a partial agonist for ER alpha with an EC 50 value of 0.05 nM. It is also an antagonist for both ER alpha and beta with IC 50 values of 0.95 nM and 4.9 nM, respectively. Data shown are representative of 2 independent experiments. Error bars represent the standard error of the mean (SEM) for n = 2 values within a single experiment. ER, estrogen receptor. . 4 . Cyproterone acetate is a partial antagonist for the androgen receptor (AR), full antagonist for the glucocorticoid receptor (GR), and partial agonist for the progesterone receptor (PR). Cells were serum starved the day prior to assay and plated in a 384-well assay plate. For agonist mode, cells were stimulated with cyproterone acetate for 16 h prior to the beta-lactamase assay (as described in Materials and Methods; PR, ). For antagonist mode, cells were stimulated with cyproterone acetate for 30 to 60 min prior to stimulation with EC 80 amounts of primary ligand (1.23 nM dihydrotestosterone for AR and 1.5 nM dexamethasone for GR) for 16 h prior to the beta-lactamase assay (as described in Materials and Methods; AR, ; GR, ). Data shown are representative of 2 independent experiments. Error bars represent the standard error of the mean (SEM) for n = 2 values within a single experiment. look at our profiling results in comparison to literature values using full-length receptors ( Table 3) .
In our chimeric MR assay, the IC 50 values for some MR antagonist compounds were as follows: spironolactone 0.13 nM, R1881 0.15 nM, testosterone 2.2 nM, and DHT >10,000 nM. Although the IC 50 values are not identical between different assay formats, the rank order potency of these compounds in our chimeric Gal4/LBD assays is the same as what has been previously described in the literature using full-length MR in the same cellular background. 14 Our chimeric estrogen receptor assays also show similar rank order potency of key compounds to a reporter assay reported in the literature using T47D cells, which express endogenous ER alpha and ER beta 18 (Table 3) . Unlike our 2 separate assays for ER alpha and ER beta, the T47D reporter gene assay cannot distinguish between the 2 isoforms of the estrogen receptor. DES is a potent agonist, similar in potency to 17β-estradiol (E2). In our assays, both of these compounds were very potent, with EC 50 values for E2 and DES of <1 pM and 2.9 pM, respectively, for ER alpha and 6 pM and 0.7 pM, respectively, for ER beta. DHT is a much weaker agonist than DES. 18 In our assays, the EC 50 for DHT was 190 nM for ER alpha and 745 nM for ER beta. The estrogen receptor antagonist ICI 182.780 also behaved similarly in our assays compared with the literature using endogenous receptors, with IC 50 values in the low nanomolar range for all assays. 18 Genistein is known to be a more potent but partial agonist for ER beta and a weaker but full agonist for ER alpha in a HEK293based full-length reporter gene assay, 12 which is also reproduced in our chimeric assays. For ER alpha, our observed EC 50 value was 816 nM, and in our ER beta assay, genistein showed partial agonist activity with an EC 50 of 196 nM. Again, although the EC 50 and IC 50 values are not always identical between different assay formats, the rank order potency of these ER ligands matches up quite nicely between our LBD assay and full-length/endogenous ER assays. 12, 18 Mometasone furoate (MF) and fluticasone propionate (FP) are potent glucocorticoids that are commonly used as antiinflammatory agents in treating respiratory diseases. The profiles of these 2 compounds in our chimeric assays ( Table 3) and those of either endogenous or full-length transfected cellular reporter gene assays in a variety of cellular backgrounds 13 are in general very similar. In most cases, comparable potencies and functional activities were observed for the compounds in all assays. Both compounds were potent GR agonists, with EC 50 values of 2 pM for MF and 3 pM for FP in our assays. MF was a strong PR agonist (EC 50 value of 12 pM for our chimeric assay), whereas FP was a weaker PR agonist (EC 50 value of 1 nM). Neither compound had any effect on ERs. Both compounds were antagonists of AR (IC 50 values of 88 nM for MF and 24 nM for FP). A slight difference between our chimeric and the full-length AR assays is that partial antagonist activity of these 2 compounds was observed in our chimeric assay, whereas in the full-length AR assay, they appeared to be full antagonists. In addition, the rank order potency was different for these 2 compounds in the AR assays. 13 Although FP was a pure MR antagonist (IC 50 value of 2 nM), MF had mixed agonist/ antagonist activities in MR. In our chimeric MR assay, partial agonist activity with an EC 50 value of 542 nM, as well as partial antagonistic activity with an IC 50 value of 0.2 nM, was obtained. Although not an exhaustive comparison by any means, this gives us confidence that in most cases, our LBD assays perform similarly to assays using the full-length or endogenous steroid hormone receptors.
DISCUSSION
Steroid nuclear receptors are widely known validated drug targets, and much research is being done in an attempt to discover selective modulators of these receptors. Many of the current drugs targeting these receptors have significant off-target side effects that limit their usefulness, and the availability of tissue-specific or receptor-specific drugs would lead to reduced side effects and better drug profiles.
A complete panel of validated chimeric Gal4-DBD/NR-LBD beta-lactamase reporter gene cellular assays was developed that can be used for HTS and selectivity profiling of modulators of steroid hormone receptors. This chimeric format is feasible because of the modular nature of NR proteins. The DBDs and LBDs of NRs can function independently of one another, and thus they can be mixed and matched and still maintain their specific binding properties. The use of Gal4-DBD/NR-LBD chimeras is a common avenue for developing cell-based assays for nuclear receptor targets and has many advantages. 9 Because Gal4 is a yeast-specific transcription factor, the use of this chimeric system leads to reduced background, less noise, and no interference from endogenous NRs when used in mammalian cells, allowing one to focus on the receptor of interest. Only the Gal4 chimeras can activate the UAS-bla reporter construct. Beta-lactamase (bla) was chosen as the reporter gene for these assays because of the ratiometric readout provided by the nontoxic, cell-permeable fluorescence resonance energy transfer (FRET)-based substrate, suitable for HTS. 19 We employed this panel of steroid NR cell lines in a screening project consisting of 35 pharmacologically relevant compounds, and the results demonstrated that this panel of steroid receptor assays can be used to identify selective nuclear receptor modulators such as SERMs and compounds with mixed or partial agonist or antagonist activities. Rank order potency and selectivity are well preserved relative to alternative cellular assay formats reported in the literature using full-length or endogenous receptors.
The ability to detect partial and mixed activities of ligands is very important for nuclear receptor assays. Partial agonists and antagonists are generally believed to have a more desirable drug profile than full agonists and antagonists, with fewer off-target side effects and a more selective profile. 20 Compounds that show partial activity have a different biological effect compared with full-activity compounds and lead to alternative conformations of the receptor compared with full-activity compounds. These alternate conformations result in differential recruitment or displacement of cofactors, as well as tissue-specific and promoter-selective expression of target genes. 20 The ability of these assays to detect partial and mixed activities of nuclear receptor modulators indicates that they could be a useful tool for the current drug discovery effort to identify new SNuRMs.
Although consistency with literature values in most cases was achieved, some differences were observed between activities of certain compounds in differing cellular assay formats, in terms of potency or partial versus full activities. For example, mometasone furoate and fluticasone propionate had partial antagonist activities in our chimeric AR assay, whereas in a different cell line transfected with the full-length AR, these compounds were full antagonists. In addition, the potency of FP varies greatly between the 2 assays. 13 There were also differences in potencies in some of the estrogenic and antimineralocorticoid compounds, though importantly, the proper rank order potency was preserved between different assay formats. 14, 18 The reasons for these discrepancies are not always clearly known. We speculate that various cellular backgrounds for different types of assays could lead to some differences in the activities of certain compounds. As described earlier, NR biology is very complex because of the various regulating cofactors, response elements, and varied tissue expression of interacting proteins. The same compound can have differing effects in different tissues, so assays created in different cellular backgrounds could yield potentially different results for the same compound. To alleviate some of these possible problems, we used the same cellular background for the complete panel of steroid receptor assays. Although this cell-based approach cannot elucidate mixed effects that a compound may have in different tissue types, it does have the ability to discern functional activity and eliminates possible crosstalk and selectivity problems that may be seen in other full-length or endogenous cellular assays. Another factor that could lead to differences in compound potencies among various cellular assay types is the level of receptor expression. We did not quantitate receptor expression levels in our assays or compare receptor expression levels with other assay formats. One could expect some discrepancies in compound efficacies if receptor levels are drastically different in various assay formats, which is why having the correct rank order potency within a particular assay is so important.
We have shown that this panel of steroid hormone receptor assays can be used individually in HTS campaigns against a particular steroid receptor target, or they can be employed in a panel to assess the relative potencies of a single compound against a series of receptors, thus obtaining specificity information about a particular compound. The developed cell lines, commercially available as GeneBLAzer™ nuclear receptor cell lines, are valuable tools in the pursuit of selective nuclear receptor modulators and in minimizing off-target side effects of drugs that target these receptors.
